IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v27y2009i1p55-68.html
   My bibliography  Save this article

Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin’s Lymphoma

Author

Listed:
  • Philippe Fagnoni
  • Noel Milpied
  • Samuel Limat
  • Eric Deconinck
  • Virginie Nerich
  • Charles Foussard
  • Philippe Colombat
  • Jean-Luc Harousseau
  • Marie-Christine Woronoff-Lemsi

Abstract

Background: The GOELAMS 072 study showed that first-line high-dose chemotherapy (HDT) with peripheral blood stem cell transplant (PBSCT) support was superior to the standard chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine and prednisone; CHOP) in adults with aggressive non-Hodgkin’s lymphoma (NHL). Objective: The aim of the study was to evaluate the pharmacoeconomic profile of HDT with PBSCT support relative to standard CHOP therapy as first-line treatment in adults with aggressive NHL. Methods: We performed a cost-effectiveness analysis from the French Public Health Insurance perspective, restricted to hospital costs (€, year 2008 values). The clinical effectiveness criterion was censured overall survival (OS) difference after a median follow-up of 4 years for the entire cohort. A total of 197 patients were included (CHOP, n=99; HDT, n=98). Uncertainty was assessed using non-parametric bootstrap simulations and various scenario analyses. Results: Five-year OS did not differ significantly between groups for the entire cohort. Nevertheless, subgroup analyses appeared to be more relevant for decision making: among patients with a high-intermediate risk according to the age-adjusted International Prognostic Index (IPI), HDT yielded a significantly higher 5-year OS than CHOP (74% vs 44%; p=0.001). Among these patients, the mean censured OS survival, adjusted for time discounting and quality of life (QOL), increased with HDT by 1.20 years (95% CI 1.19, 1.21). The cost per life-year saved with HDT was estimated as h34 315 (95% CI 32 683, 35 947) in this subgroup. Conclusion: Results suggested thatHDT with PBSCT supportmight be considered a cost-effective strategy among patients with high-intermediate-risk NHL according to the age-adjusted IPI. Its place and its cost effectiveness potential versus, or in combination with, rituximab still need further research. Copyright Adis Data Information BV 2009

Suggested Citation

  • Philippe Fagnoni & Noel Milpied & Samuel Limat & Eric Deconinck & Virginie Nerich & Charles Foussard & Philippe Colombat & Jean-Luc Harousseau & Marie-Christine Woronoff-Lemsi, 2009. "Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin’s Lymphoma," PharmacoEconomics, Springer, vol. 27(1), pages 55-68, January.
    • Handle: RePEc:spr:pharme:v:27:y:2009:i:1:p:55-68
    DOI: 10.2165/00019053-200927010-00006
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200927010-00006
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200927010-00006?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Andrew H. Briggs & David E. Wonderling & Christopher Z. Mooney, 1997. "Pulling cost‐effectiveness analysis up by its bootstraps: A non‐parametric approach to confidence interval estimation," Health Economics, John Wiley & Sons, Ltd., vol. 6(4), pages 327-340, July.
    2. A. Pickard & Caitlyn Wilke & Hsiang-Wen Lin & Andrew Lloyd, 2007. "Health Utilities Using the EQ-5D in Studies of Cancer," PharmacoEconomics, Springer, vol. 25(5), pages 365-384, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Iris Arends & Ute Bültmann & Willem van Rhenen & Henk Groen & Jac J L van der Klink, 2013. "Economic Evaluation of a Problem Solving Intervention to Prevent Recurrent Sickness Absence in Workers with Common Mental Disorders," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-1, August.
    2. Daniel F. Heitjan & Alan J. Moskowitz & William Whang, 1999. "Problems with Interval Estimates of the Incremental Cost—Effectiveness Ratio," Medical Decision Making, , vol. 19(1), pages 9-15, January.
    3. Andrew Briggs & Paul Fenn, 1998. "Confidence intervals or surfaces? Uncertainty on the cost‐effectiveness plane," Health Economics, John Wiley & Sons, Ltd., vol. 7(8), pages 723-740, December.
    4. Feng Xie & Ngai-Nung Lo & Jean-Eric Tarride & Daria O’Reilly & Ron Goeree & Hin-Peng Lee, 2010. "Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 27-34, February.
    5. Mohsen Sadatsafavi; & Carlo Marra; & Lawrence McCandless & Stirling Bryan, 2012. "The challenge of incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods," Health, Econometrics and Data Group (HEDG) Working Papers 12/24, HEDG, c/o Department of Economics, University of York.
    6. James W. Shaw & William C. Horrace & Ronald J. Vogel, 2002. "The Productivity of Pharmaceuticals in Improving Health: An Analysis of the OECD Health Data," HEW 0206001, University Library of Munich, Germany, revised 11 May 2003.
    7. Anthony O'Hagan & John W. Stevens, 2003. "Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?," Health Economics, John Wiley & Sons, Ltd., vol. 12(1), pages 33-49, January.
    8. Daniel F. Heitjan & Alan J. Moskowitz & William Whang, 1999. "Bayesian estimation of cost‐effectiveness ratios from clinical trials," Health Economics, John Wiley & Sons, Ltd., vol. 8(3), pages 191-201, May.
    9. González-Gómez, Manuel & Álvarez-Díaz, Marcos & Otero-Giráldez, María Soledad, 2013. "Estimating the long-run impact of forest fires on the eucalyptus timber supply in Galicia, Spain," Journal of Forest Economics, Elsevier, vol. 19(2), pages 149-161.
    10. Elisa Sicuri & Azucena Bardají & Tacilta Nhampossa & Maria Maixenchs & Ariel Nhacolo & Delino Nhalungo & Pedro L Alonso & Clara Menéndez, 2010. "Cost-Effectiveness of Intermittent Preventive Treatment of Malaria in Pregnancy in Southern Mozambique," PLOS ONE, Public Library of Science, vol. 5(10), pages 1-10, October.
    11. David J. Vanness & W. Ray Kim, 2002. "Bayesian estimation, simulation and uncertainty analysis: the cost‐effectiveness of ganciclovir prophylaxis in liver transplantation," Health Economics, John Wiley & Sons, Ltd., vol. 11(6), pages 551-566, September.
    12. An Tran-Duy & Annelies Boonen & Wietske Kievit & Piet Riel & Mart Laar & Johan Severens, 2014. "Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 32(10), pages 1015-1028, October.
    13. Andrew H. Briggs, 1999. "A Bayesian approach to stochastic cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 8(3), pages 257-261, May.
    14. Mercedes Mareque & Elena de Prada Creo & Marcos Álvarez-Díaz, 2021. "Exploring Creative Tourism Based on the Cultural and Creative Cities (C3) Index and Using Bootstrap Confidence Intervals," Sustainability, MDPI, vol. 13(9), pages 1-17, May.
    15. Pinto-Prades, Jose Luis & Loomes, Graham & Brey, Raul, 2009. "Trying to estimate a monetary value for the QALY," Journal of Health Economics, Elsevier, vol. 28(3), pages 553-562, May.
    16. S. Olofsson & U.-G. Gerdtham & L. Hultkrantz & U. Persson, 2018. "Measuring the end-of-life premium in cancer using individual ex ante willingness to pay," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(6), pages 807-820, July.
    17. Andrew Briggs, 2012. "Statistical Methods for Cost-effectiveness Analysis Alongside Clinical Trials," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 50, Edward Elgar Publishing.
    18. Marcos Álvarez-Díaz, 2020. "Is it possible to accurately forecast the evolution of Brent crude oil prices? An answer based on parametric and nonparametric forecasting methods," Empirical Economics, Springer, vol. 59(3), pages 1285-1305, September.
    19. Manca, A & Austin, P. C, 2008. "Using propensity score methods to analyse individual patient-level cost-effectiveness data from observational studies," Health, Econometrics and Data Group (HEDG) Working Papers 08/20, HEDG, c/o Department of Economics, University of York.
    20. Bettina Wulff Risør & Marianne Lisby & Jan Sørensen, 2018. "Comparative Cost-Effectiveness Analysis of Three Different Automated Medication Systems Implemented in a Danish Hospital Setting," Applied Health Economics and Health Policy, Springer, vol. 16(1), pages 91-106, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:27:y:2009:i:1:p:55-68. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.